- Home
- CLLS vs LCTX Comparison
CLLS vs LCTX Comparison
Compare CLLS & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- LCTX
- Stock Information
- Founded
- CLLS 1999
- LCTX 1990
- Country
- CLLS France
- LCTX United States
- Employees
- CLLS N/A
- LCTX N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLLS Health Care
- LCTX Health Care
- Exchange
- CLLS Nasdaq
- LCTX Nasdaq
- Market Cap
- CLLS 148.1M
- LCTX 118.8M
- IPO Year
- CLLS 2007
- LCTX N/A
- Fundamental
- Price
- CLLS $1.24
- LCTX $0.45
- Analyst Decision
- CLLS Buy
- LCTX Strong Buy
- Analyst Count
- CLLS 3
- LCTX 5
- Target Price
- CLLS $7.00
- LCTX $4.20
- AVG Volume (30 Days)
- CLLS 836.8K
- LCTX 1.8M
- Earning Date
- CLLS 03-13-2025
- LCTX 03-10-2025
- Dividend Yield
- CLLS N/A
- LCTX N/A
- EPS Growth
- CLLS N/A
- LCTX N/A
- EPS
- CLLS N/A
- LCTX N/A
- Revenue
- CLLS $49,217,000.00
- LCTX $9,499,000.00
- Revenue This Year
- CLLS $1.26
- LCTX $25.10
- Revenue Next Year
- CLLS N/A
- LCTX $35.67
- P/E Ratio
- CLLS N/A
- LCTX N/A
- Revenue Growth
- CLLS 435.38
- LCTX 6.19
- 52 Week Low
- CLLS $1.14
- LCTX $0.46
- 52 Week High
- CLLS $3.38
- LCTX $1.56
- Technical
- Relative Strength Index (RSI)
- CLLS 38.55
- LCTX 33.77
- Support Level
- CLLS $1.28
- LCTX $0.47
- Resistance Level
- CLLS $1.35
- LCTX $0.55
- Average True Range (ATR)
- CLLS 0.07
- LCTX 0.03
- MACD
- CLLS 0.01
- LCTX 0.00
- Stochastic Oscillator
- CLLS 38.46
- LCTX 11.21
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.